GlassScriptPhysician profile
Michelle Mccaskill
NPI 1235278292
$1,623.69
in general payments reported to CMS, 2019-2025
16 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $231 · 2023: $336 · 2024: $462 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $464.83 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $254.14 | 2022-2024 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $168.80 | 2024-2025 | |
| Glaxosmithkline, LLC. | $134.70 | 2021-2025 | Bexsero |
| Pfizer INC. | $105.28 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $92.19 | 2021-2024 | Qelbree |
| Merck Sharp & Dohme LLC | $83.56 | 2021-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Kaleo, INC. | $54.59 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $53.67 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $52.38 | 2023-2024 | Ycanth |
| Sobi, INC | $45.81 | 2021-2023 | Synagis |
| Takeda Pharmaceuticals U.S.A., INC. | $29.28 | 2021 | |
| Biomarin Pharmaceutical INC. | $27.28 | 2024 | Voxzogo 1.2mg |
| Seqirus USA INC | $21.77 | 2025 | Flucelvax |
| Acadia Pharmaceuticals INC | $19.50 | 2023 | Daybue |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $15.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mccaskill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.